Invega Sustenna (paliperidone palmitate) is a prescription drug that’s used to treat schizophrenia and schizoaffective disorder. Invega Sustenna is given as an injection into your muscle by a ...

JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end.

Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest ...

Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for ...

If you are worried about using this medicine, speak to your doctor or pharmacist. INVEGA HAFYERA contains the active ingredient paliperidone palmitate. INVEGA HAFYERA is used to treat ...

Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Johnson & Johnson (JNJ – Research Report). The associated ...

The period is expected to feature launches of new branded drugs, along with tough years for the long-acting injectables (LAI) Abilify Maintena, Aristada and Invega Sustenna, all of which are set ...

A key rival could be Johnson & Johnson's recently-approved Invega Hafyera (paliperidone), which only needs to be administered twice-yearly, as well as J&J's older monthly and three-monthly ...

Johnson & Johnson kicked off the J.P. Morgan Healthcare Conference on Monday with the $14.6 billion acquisition of Intra-Cellular Therapies.

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire ...

Second place was Johnson & Johnson’s schizophrenia treatment Invega Sustenna/Invega Trinza (paliperidone), with a 6.8% increase in the list price – and 10.7% net – which added $203 million ...

unsealed ruling shows Schizophrenia drug had nearly $3 billion in US sales in 2023 Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit convinced a federal judge that unexpected results and industry ...